(Q40394531)

English

Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit--multicenter studies of the French LAME (Leucémie Aiguë Myéloblastique Enfant) Cooperative Group

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit--multicenter studies of the French LAME (Leucémie Aiguë Myéloblastique Enfant) Cooperative Group (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

multicenter clinical trial

0 references

Acute myeloblastic leukemia

1 reference

based on heuristic

inferred from title

childhood acute myeloid leukemia

1 reference

based on heuristic

inferred from title

author name string

Y Perel

1

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

A Auvrignon

2

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

T Leblanc

3

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

G Michel

4

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Y Reguerre

5

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

J-P Vannier

6

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

J-H Dalle

7

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

V Gandemer

8

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

C Schmitt

9

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

F Méchinaud

10

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

O Lejars

11

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

C Piguet

12

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

G Couillaud

13

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

B Pautard

14

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

J Landman-Parker

15

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

I Thuret

16

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

N Aladjidi

17

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

A Baruchel

18

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

G Leverger

19

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

French LAME (Leucémie Aiguë Myéloblastique Enfant) Cooperative Group

20

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

publication date

1 December 2005

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

19

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

2082-2089

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403867

0 references

Impact of addition of maintenance therapy to intensive induction and consolidation chemotherapy for childhood acute myeloblastic leukemia: results of a prospective randomized trial, LAME 89/91. Leucámie Aiqüe Myéloïde Enfant.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403867

21 January 2018

A population-based study of 272 children with acute myeloid leukaemia treated on two consecutive protocols with different intensity: best outcome in girls, infants, and children with Down's syndrome. Nordic Society of Paediatric Haematology and Onco

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403867

21 January 2018

Treatment stratification based on initial in vivo response in acute myeloid leukaemia in children without Down's syndrome: results of NOPHO-AML trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403867

21 January 2018

Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403867

21 January 2018

Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403867

21 January 2018

Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403867

21 January 2018

Treatment-related deaths during induction and first remission of acute myeloid leukaemia in children treated on the Tenth Medical Research Council acute myeloid leukaemia trial (MRC AML10). The MCR Childhood Leukaemia Working Party

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403867

21 January 2018

MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403867

21 January 2018

Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403867

21 January 2018

BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403867

21 January 2018

FLT3-TKD mutation in childhood acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403867

21 January 2018

Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403867

21 January 2018

Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403867

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403867

7 January 2021

based on heuristic

inferred from DOI database lookup

Allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: impact of conditioning regimen without total-body irradiation--a report from the Société Française de Greffe de Moelle

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403867

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aique Myeloide Enfant (LAME) 89/91 protocol of the French Society of Pediatric Hematology and Immunology

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403867

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403867

7 January 2021

based on heuristic

inferred from DOI database lookup

A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403867

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of high-dose cytarabine and asparaginase intensification on childhood acute myeloid leukemia: a report from the Childrens Cancer Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403867

7 January 2021

based on heuristic

inferred from DOI database lookup

6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403867

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of newly diagnosed children and adolescents with acute myeloid leukemia: a Childrens Cancer Group study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403867

7 January 2021

based on heuristic

inferred from DOI database lookup

Expression of endothelial cell-associated molecules in AML cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403867

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.LEU.2403867

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40394531&oldid=1896784478"